JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation

Leukemia. 2018 Aug;32(8):1842-1845. doi: 10.1038/s41375-018-0145-6. Epub 2018 Apr 24.

Authors

Wenbin Xiao¹, Raajit Rampal², Yanming Zhang³, Robert Cimera³, Achim A Jungbluth⁴, Maria Arcila⁵, Mikhail Roshal⁴, David C Park^{4

6}

Affiliations

¹ Hematopathology Diagnostic Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].
² Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Cytogenetic Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Hematopathology Diagnostic Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Diagnostic Molecular Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁶ Department of Pathology, Columbia University Medical Center, New York, NY, USA.

No abstract available

Publication types

Case Reports
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
Cell Differentiation*
Erythroid Cells / metabolism
Erythroid Cells / pathology*
Extracellular Signal-Regulated MAP Kinases / genetics
Extracellular Signal-Regulated MAP Kinases / metabolism
Humans
Janus Kinase 2 / genetics
Janus Kinase 2 / metabolism
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / pathology*
Male
Megakaryocytes / metabolism
Megakaryocytes / pathology*
Middle Aged
Mutation*
Prognosis
Signal Transduction*
Tumor Suppressor Protein p53 / genetics*

Substances

Biomarkers, Tumor
TP53 protein, human
Tumor Suppressor Protein p53
JAK2 protein, human
Janus Kinase 2
Extracellular Signal-Regulated MAP Kinases

Grants and funding